Publication: The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer-Hyperthermia versus Normothermia: A Randomized Controlled Trial.
Loading...
Identifiers
Date
2022-09-28
Authors
Casado-Adam, Angela
Rodriguez-Ortiz, Lidia
Rufian-Peña, Sebastian
Muñoz-Casares, Cristobal
Caro-Cuenca, Teresa
Ortega-Salas, Rosa
Fernandez-Peralbo, Maria Auxiliadora
Luque-de-Castro, Maria Dolores
Sanchez-Hidalgo, Juan M
Hervas-Martinez, Cesar
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Abstract
The treatment of ovarian carcinomatosis with cytoreductive surgery and HIPEC is still controversial. The effect and pharmacokinetics of the chemotherapeutics used (especially taxanes) are currently under consideration. A phase II, simple blind and randomized controlled trial (NTC02739698) was performed. The trial included 32 patients with primary or recurrent ovarian carcinomatosis undergoing cytoreductive surgery (CRS) and intraoperative intraperitoneal chemotherapy with paclitaxel (PTX): 16 in hyperthermic (42-43 °C) and 16 in normothermic (37 °C) conditions. Tissue, serum and plasma samples were taken in every patient before and after intraperitoneal chemotherapy to measure the concentration of PTX. To analyze the immunohistochemical profile of p53, p27, p21, ki67, PCNA and caspase-3 and the pathological response, a scale of intensity and percentage of expression and a grouped Miller and Payne system were used, respectively. Perioperative characteristics and morbi-mortality were also analyzed. The main characteristics of patients, surgical morbidity, hemotoxicity and nephrotoxicity were similar in both groups. The concentration of paclitaxel in the tissue was higher than that observed in plasma and serum, although no statistically significant differences were found between the two groups. No statistically significant association regarding pathological response and apoptosis (caspase-3) between both groups was proved. There were no statistically significant differences between the normothermic and the hyperthermic group for pathological response and apoptosis. The use of intraperitoneal PTX has proven adequate pharmacokinetics with reduction of cell cycle and proliferation markers globally without finding statistically significant differences between its administration under hyperthermia versus normothermia conditions.
Description
MeSH Terms
Cytoreduction surgical procedures
Taxoids
Peritoneal neoplasms
Hyperthermia, induced
Cell cycle
Cell division
Hyperthermia
Taxoids
Peritoneal neoplasms
Hyperthermia, induced
Cell cycle
Cell division
Hyperthermia
DeCS Terms
Ciclo celular
División celular
Hipertermia
Hipertermia inducida
Neoplasias peritoneales
Procedimientos quirúrgicos de citorreducción
Taxoides
División celular
Hipertermia
Hipertermia inducida
Neoplasias peritoneales
Procedimientos quirúrgicos de citorreducción
Taxoides
CIE Terms
Keywords
Intraperitoneal chemotherapy, Ovarian cancer, Peritoneal carcinomatosis
Citation
Casado-Adam A, Rodriguez-Ortiz L, Rufian-Peña S, Muñoz-Casares C, Caro-Cuenca T, Ortega-Salas R, et al. The Role of Intraperitoneal Intraoperative Chemotherapy with Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis from Ovarian Cancer-Hyperthermia versus Normothermia: A Randomized Controlled Trial. J Clin Med. 2022 Sep 29;11(19):5785